A Bad Sign: Dermatomyositis with Interstitial Lung Disease

Palawisuth, Siriwan; Kantikosum, Kornphaka; Patiyasikunt, Mattana; Sriprasart, Thitiwat; Asawanonda, Pravit; Rerknimitr, Pawinee

doi:10.1016/j.amjmed.2018.09.013

Cited by 8 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient presented with subjective proximal muscle weakness and had a normal CK level, while a second patient endorsed proximal muscle weakness and tenderness with an elevated CK. 3 , 4 Thus, anti-MDA5 antibody-associated dermatomyositis usually presents without myositis, but a spectrum of muscle involvement is possible.…”

Section: Discussionmentioning

confidence: 99%

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review

et al. 2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review

et al. 2021

View full text Add to dashboard Cite

“…5,6 Interstitial lung disease is also not uncommon and is often associated with rapid progression. 7 In addition, patients with DM are more likely than those with polymyositis to develop pulmonary complications such as subcutaneous emphysema, pneumothorax, and pneumomediastinum. 6 Though these complications are rare, their occurrence is serious and might be associated with fatal outcomes.…”

Section: Introductionmentioning

confidence: 99%

Spontaneous Pneumomediastinum and Subcutaneous Emphysema in Dermatomyositis: A Case Series and Literature Review

Subki¹,

Almani²,

Albeity³

et al. 2023

JIR

View full text Add to dashboard Cite

Background: Spontaneous pneumomediastinum and subcutaneous emphysema are rare and serious complications of dermatomyositis (DM). Case Presentation: Our article presents two clinically heterogeneous cases of DM who developed pneumomediastinum and subcutaneous emphysema. The first was a 24-year-old lady with a recently diagnosed DM. She developed rapidly progressive pneumonia, interstitial lung disease (ILD), pneumomediastinum, subcutaneous emphysema, and acute respiratory distress syndrome (ARDS). She died despite treatment with steroids and immunosuppressants (methotrexate and mycophenolate mofetil (MMF)). The second was a 30-year-old man diagnosed with amyopathic DM. He developed pneumomediastinum prior to ILD, which worsened over time, and subcutaneous emphysema evolved. However, he recovered completely after corticosteroid, MMF, and rituximab. Conclusion: Spontaneous pneumomediastinum and subcutaneous emphysema may complicate DM. Corticosteroids, immunosuppressants, and respiratory support are the mainstay of management for these conditions. Though they were reported to carry a poor prognostic value, the course and outcome are highly variable among the cases.

show abstract

Comparative analysis of connective tissue disease–associated interstitial lung disease and interstitial pneumonia with autoimmune features

et al. 2019

View full text Add to dashboard Cite

A Bad Sign: Dermatomyositis with Interstitial Lung Disease

Cited by 8 publications

References 20 publications

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review

Anti-MDA5 Antibody-Associated Clinically Amyopathic Dermatomyositis: Case Report and Literature Review

Spontaneous Pneumomediastinum and Subcutaneous Emphysema in Dermatomyositis: A Case Series and Literature Review

Comparative analysis of connective tissue disease–associated interstitial lung disease and interstitial pneumonia with autoimmune features

Contact Info

Product

Resources

About